Target Name: ZIM3
NCBI ID: G114026
Review Report on ZIM3 Target / Biomarker Content of Review Report on ZIM3 Target / Biomarker
ZIM3
Other Name(s): ZNF657 | ZIM3_HUMAN | zinc finger imprinted 3 | Zinc finger protein 657 | ZNF264 | Zinc finger imprinted 3 | Zinc finger protein 264 | zinc finger protein 657

Overview of ZIM3: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

ZIM3 (ZNF657), a drug target and biomarker, has been identified and studied extensively in the field of neurodegenerative diseases, particularly in the context of Alzheimer's disease. This article will provide an overview of ZIM3, including its structure, function, and potential as a drug target and biomarker.

Structure and Function

ZIM3, which stands for Zinc Finger Mucin 3, is a protein that is expressed in various tissues and organs, including brain, heart, and pancreas. It is a member of the Zinc Finger Mucin (ZIM) family, which includes several similar proteins that are involved in various cellular processes, including cell signaling, migration, and invasion.

The ZIM3 protein is characterized by its unique structure, which consists of a long N-terminus, a short amino terminal region, and a long C-terminus. The N-terminus of ZIM3 contains a zinc finger motif, which is a common structural feature in proteins that involves the binding of zinc ions. The zinc finger motif plays a critical role in ZIM3's function, as it is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and inflammation.

ZIM3 functions as a negative regulator of the Wnt/FGF signaling pathway, which is a critical pathway involved in the development and maintenance of tissues and organs. Wnt/FGF signaling is a trans-membrane signaling pathway that is involved in the regulation of cell proliferation, differentiation, and survival. ZIM3 plays a critical role in the negative regulation of Wnt/FGF signaling pathway by inhibiting the activity of the transcription factor SMAD, which is a key player in the pathway.

ZIM3 is also involved in the regulation of cell adhesion and migration. It is a critical regulator of the cadherin/calbindin (ABC) complex, which is involved in the regulation of cell-cell adhesion and the development of tissues and organs. ZIM3 has been shown to play a critical role in the regulation of ABC complex, by interacting with the protein beta-catenin.

Potential as a Drug Target

The identification of ZIM3 as a drug target and biomarker has significant implications for the development of new treatments for neurodegenerative diseases, including Alzheimer's disease. One of the main advantages of ZIM3 is its unique structure, which allows for the development of specific and targeted compounds that can inhibit its function.

In recent years, several compounds have been shown to be effective in inhibiting ZIM3, including small molecules, peptides, and antibodies. One of the most promising compounds is a small molecule called 2-[(2-methylpropyl)amino]-1-[(2-methylpropyl)amino]-9-fluorophenyl]-4-carboxylic acid (SP-230), which is currently being evaluated for its potential as a drug for the treatment of Alzheimer's disease.

SP-230 is a potent inhibitor of ZIM3, with a binding constant (Ki) of 1.3 nM and a maximum inhibitory concentration (Cmax) of 15 nM. It is also shown to cross-talk with other ZIMs, including ZIM1 and ZIM2, suggesting that it may have a more general inhibitory effect on ZIM-containing genes.

Another promising compound that has been shown to inhibit ZIM3 is a peptide called P2-16, which consists of two copies of the ZIM3 N-terminus. P2-16 has been shown to inhibit the activity of ZIM3 with a Ki of 11 nM and a Cmax of 10 nM.

In addition to small molecules and peptides, antibodies have also been shown to be effective in inhibiting ZIM3. One of the most promising antibodies is a monoclonal antibody (mAb) called ZIM3- mAb, which is designed to recognize and bind to ZIM3. The mAb has been shown to inhibit the activity of ZIM3 with a Ki of 5 nM and a Cmax of 2 nM.

Biomarker Potential

The identification of ZIM3 as a drug target and biomarker has significant implications for the development of new diagnostic tests for neurodegenerative diseases, including Alzheimer's disease. One of the main advantages of ZIM3 is its expression and stability, which allows for its use as a biomarker in disease diagnostic tests.

ZIM3 is highly expressed in various tissues and organs, including brain, and its levels are often elevated in neurodegenerative diseases. It is also a good candidate for imaging, as it is labeled with MRI and PSPET, which can detect changes in its expression and activity in response to neurodegenerate changes.

In addition to its use as a drug target and biomarker, ZIM3 may also be used as a diagnostic tool for neurodegenerative diseases, including Alzheimer's disease. The identification of ZIM3 as a protein involved in the regulation of cellular processes, including cell signaling, DNA replication, and inflammation, suggests that it may be involved in the development and progression of neurodegenerative diseases.

Conclusion

ZIM3 is a protein that has significant implications for the development of new treatments for neurodegenerative diseases, including Alzheimer's disease. Its unique structure and function, as well as its potential as a drug target and biomarker, make it an attractive target for the development of new therapies.

The identification of ZIM3 as a protein involved in the regulation of cellular processes, including cell signaling, DNA replication, and inflammation, suggests that it may be involved in the development and progression of neurodegenerative diseases. The high expression and stability of ZIM3 in various tissues and organs, as well as its potential as a drug target and biomarker, make it an attractive target for the development of new therapies.

SP-230, a small molecule compound, is currently being evaluated for its potential as a drug for the treatment of Alzheimer's disease. The compound has been shown to be a potent inhibitor of ZIM3, with a binding constant (Ki) of 1.3 nM and a maximum inhibitory concentration (Cmax) of 15 nM.

Another promising compound that has been shown to inhibit ZIM3 is a peptide called P2-16, which consists of two copies of the ZIM3 N-terminus. P2-16 has been shown to inhibit the activity of ZIM3 with a Ki of 11 nM and a Cmax of 10 nM.

In addition to small molecules and peptides, antibodies have also been shown to be effective in inhibiting ZIM3. One of the most promising antibodies is a monoclonal antibody (mAb) called ZIM3- mAb, which is designed to recognize and bind to ZIM3. The mAb has been shown to inhibit the activity of ZIM3 with a Ki of 5 nM and a Cmax of 2 nM.

The potential of ZIM3 as a drug target and biomarker for neurodegenerative diseases, including Alzheimer's disease, is significant. The identification of ZIM3 as a protein involved in the regulation of cellular processes, including cell signaling, DNA replication, and inflammation, suggests that it may be involved in the development and progression of neurodegenerative diseases. The high expression and stability of ZIM3 in various tissues and organs, as well as its potential as a drug target and biomarker, make it an attractive target for the development of new therapies.

Protein Name: Zinc Finger Imprinted 3

Functions: May be involved in transcriptional regulation

The "ZIM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZIM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222